NASDAQ:KITE - Kite Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$179.79 0.00 (0.00 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$179.79
Today's Range$179.79 - $179.79
52-Week Range$39.82 - $179.99
VolumeN/A
Average Volume1.65 million shs
Market Capitalization$10.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Kite Pharma (NASDAQ:KITE)

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01
Quick Ratio9.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,092.54%
Return on Equity-59.15%
Return on Assets-48.12%

Miscellaneous

Employees447
Outstanding Shares57,370,000

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analysts' expectations of $5.74 million. Kite Pharma had a negative return on equity of 59.15% and a negative net margin of 1,092.54%. Kite Pharma's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.54) EPS. View Kite Pharma's Earnings History.

What price target have analysts set for KITE?

11 brokers have issued 1 year price objectives for Kite Pharma's stock. Their predictions range from $54.00 to $135.00. On average, they anticipate Kite Pharma's share price to reach $99.00 in the next year. View Analyst Ratings for Kite Pharma.

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

Has Kite Pharma been receiving favorable news coverage?

News headlines about KITE stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.23 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Kite Pharma?

Shares of KITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

How big of a company is Kite Pharma?

Kite Pharma has a market capitalization of $10.28 billion. Kite Pharma employs 447 workers across the globe.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (KITE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  638 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  939
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kite Pharma (NASDAQ:KITE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Kite Pharma in the last 12 months. Their average twelve-month price target is $99.00, suggesting that the stock has a possible downside of 44.94%. The high price target for KITE is $135.00 and the low price target for KITE is $54.00. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.432.392.39
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $99.00$94.25$93.20$93.20
Price Target Upside: 44.94% downside47.07% downside47.66% downside47.66% downside

Kite Pharma (NASDAQ:KITE) Consensus Price Target History

Price Target History for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ:KITE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform ➝ NeutralLowView Rating Details
8/29/2017Canaccord GenuityDowngradeBuy ➝ HoldLowView Rating Details
8/28/2017GuggenheimDowngradeBuy ➝ Neutral$128.00LowView Rating Details
8/28/2017SunTrust BanksDowngradeBuy ➝ HoldMediumView Rating Details
8/28/2017BTIG ResearchDowngradeBuy ➝ NeutralHighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$74.00LowView Rating Details
8/9/2017Jefferies GroupReiterated RatingBuy$121.00 ➝ $135.00LowView Rating Details
7/13/2017Maxim GroupDowngradeBuy ➝ Hold$88.00LowView Rating Details
7/4/2017Roth CapitalReiterated RatingBuy$93.00MediumView Rating Details
7/4/2017CowenReiterated RatingOutperformMediumView Rating Details
5/30/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/19/2017HC WainwrightReiterated RatingBuy$85.00MediumView Rating Details
5/15/2017Raymond JamesDowngradeOutperform ➝ Mkt PerformN/AView Rating Details
5/9/2017Goldman Sachs GroupBoost Price TargetBuy$85.00 ➝ $89.00HighView Rating Details
5/8/2017UBSDowngradeOutperform ➝ Market PerformN/AView Rating Details
3/13/2017Standpoint ResearchDowngradeBuy ➝ Hold$85.00LowView Rating Details
3/6/2017Royal Bank of CanadaBoost Price TargetOutperform$85.00 ➝ $95.00N/AView Rating Details
3/2/2017CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $87.00N/AView Rating Details
2/22/2017Wells Fargo & CoInitiated CoverageMarket Perform ➝ Market PerformN/AView Rating Details
9/27/2016BarclaysBoost Price TargetEqual Weight$60.00 ➝ $65.00N/AView Rating Details
8/9/2016MizuhoSet Price TargetBuy$80.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Kite Pharma (NASDAQ:KITE) Earnings History and Estimates Chart

Earnings by Quarter for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ:KITE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($2.26)($1.89)($2.08)
Q2 20182($2.26)($1.74)($2.00)
Q3 20182($2.21)($1.81)($2.01)
Q4 20182($1.96)($1.80)($1.88)

Kite Pharma (NASDAQ KITE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.97)($1.94)$9.59 million$10.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.68)($1.74)$8.85 million$9.80 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.75)($1.70)$5.74 million$4.90 millionViewListenView Earnings Details
11/9/2016Q316($1.68)($1.49)$4.94 million$7.34 millionViewListenView Earnings Details
8/8/2016Q216($1.21)($0.91)$4.86 million$4.80 millionViewN/AView Earnings Details
5/9/2016Q116($1.08)($0.90)$4.61 million$5.10 millionViewN/AView Earnings Details
2/29/2016Q4($0.71)($0.85)$4.54 million$4.89 millionViewListenView Earnings Details
11/12/2015Q315($0.64)($0.63)$4.06 million$5.10 millionViewListenView Earnings Details
8/10/2015Q215($0.41)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details
5/15/2015Q115$1.16($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details
3/26/2015Q414($0.16)($0.33)ViewN/AView Earnings Details
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.06)($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kite Pharma (NASDAQ:KITE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kite Pharma (NASDAQ KITE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 87.72%
Insider Trading History for Kite Pharma (NASDAQ:KITE)
Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Kite Pharma (NASDAQ KITE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2017Arie BelldegrunChairmanSell26,347$179.66$4,733,502.02135,507View SEC Filing  
9/25/2017Cynthia M ButittaCOOSell4,228$179.66$759,602.48125,795View SEC Filing  
9/25/2017David D. ChangEVPSell7,927$179.66$1,424,164.82View SEC Filing  
9/25/2017Jeffrey WiezorekSVPSell5,283$179.66$949,143.78View SEC Filing  
9/25/2017Paul L. JenkinsonCFOSell948$179.66$170,317.68View SEC Filing  
9/25/2017Shawn TomaselloInsiderSell4,203$179.66$755,110.98View SEC Filing  
8/10/2017Cynthia M ButittaCOOSell15,000$120.72$1,810,800.00132,795View SEC Filing  
8/10/2017Helen Susan KimEVPSell6,251$120.09$750,682.5922,259View SEC Filing  
8/8/2017Helen Susan KimEVPSell79,949$119.56$9,558,702.4498,613View SEC Filing  
8/3/2017Timothy L MooreEVPSell6,000$110.06$660,360.0055,400View SEC Filing  
8/1/2017Timothy L MooreEVPSell12,000$107.69$1,292,280.0061,400View SEC Filing  
7/31/2017Helen Susan KimEVPSell26,649$109.28$2,912,202.7228,763View SEC Filing  
7/10/2017Cynthia M ButittaCOOSell15,000$103.09$1,546,350.00132,795View SEC Filing  
7/3/2017Jeffrey WiezorekSVPSell10,000$104.32$1,043,200.0031,071View SEC Filing  
6/26/2017Owen N WitteDirectorSell25,000$100.30$2,507,500.0098,750View SEC Filing  
6/23/2017Cynthia M ButittaCOOSell5,000$100.81$504,050.00114,845View SEC Filing  
6/16/2017Farah ChampsiDirectorSell20,450$89.79$1,836,205.50View SEC Filing  
6/14/2017Steven B RuchefskyDirectorSell20,000$89.48$1,789,600.00205,426View SEC Filing  
6/9/2017Cynthia M ButittaCOOSell10,000$88.55$885,500.00127,795View SEC Filing  
6/8/2017Roy DoumaniDirectorSell15,000$84.48$1,267,200.00155,017View SEC Filing  
5/10/2017Paul L. JenkinsonCFOBuy3,450$72.59$250,435.50View SEC Filing  
5/9/2017Arie BelldegrunChairmanBuy17,000$68.57$1,165,690.0085,507View SEC Filing  
5/9/2017David BondermanDirectorBuy50,000$68.94$3,447,000.001,950View SEC Filing  
5/1/2017David D ChangEVPSell20,000$82.09$1,641,800.0070,165View SEC Filing  
4/28/2017Farah ChampsiDirectorSell19,168$82.75$1,586,152.0079,152View SEC Filing  
4/26/2017Farah ChampsiDirectorSell123,913$82.67$10,243,887.7179,152View SEC Filing  
4/25/2017Cynthia M ButittaCOOSell15,000$81.85$1,227,750.00132,795View SEC Filing  
4/25/2017Farah ChampsiDirectorSell46,783$82.80$3,873,632.4079,152View SEC Filing  
4/24/2017Farah ChampsiDirectorSell25,818$82.34$2,125,854.1279,152View SEC Filing  
4/17/2017Farah ChampsiDirectorSell115,376$82.42$9,509,289.92View SEC Filing  
4/3/2017Cynthia M ButittaCOOSell5,000$81.96$409,800.00122,795View SEC Filing  
4/3/2017Helen Susan KimEVPSell2,400$81.80$196,320.0021,064View SEC Filing  
3/27/2017Cynthia M ButittaCOOSell10,000$77.67$776,700.00127,795View SEC Filing  
3/15/2017Timothy L MooreEVPSell7,511$83.31$625,741.4141,889View SEC Filing  
3/9/2017Cynthia M ButittaCOOSell21,118$80.78$1,705,912.04138,913View SEC Filing  
3/1/2017Cynthia M ButittaCOOSell38,882$73.46$2,856,271.72127,795View SEC Filing  
3/1/2017Helen Susan KimEVPSell50,300$67.78$3,409,334.0050,265View SEC Filing  
3/1/2017Jeffrey WiezorekSVPSell18,000$75.01$1,350,180.00View SEC Filing  
3/1/2017Roy DoumaniDirectorSell18,800$74.46$1,399,848.00121,017View SEC Filing  
2/27/2017Cynthia M ButittaCOOSell10,000$54.42$544,200.00127,795View SEC Filing  
1/31/2017Cynthia M ButittaCOOSell10,000$50.56$505,600.00127,795View SEC Filing  
1/6/2017Cynthia M ButittaCOOSell10,000$50.13$501,300.00127,795View SEC Filing  
1/6/2017Jeffrey WiezorekSVPSell1,500$50.00$75,000.0022,195View SEC Filing  
12/20/2016Arie BelldegrunChairmanSell3,493$50.86$177,653.9824,707View SEC Filing  
12/20/2016Cynthia M ButittaCOOSell2,482$50.86$126,234.5292,995View SEC Filing  
12/20/2016David D. ChangEVPSell1,788$50.86$90,937.68View SEC Filing  
12/20/2016Jeffrey WiezorekSVPSell716$50.86$36,415.7615,095View SEC Filing  
12/20/2016Shawn TomaselloInsiderSell4,901$50.86$249,264.86View SEC Filing  
12/1/2016Jeffrey WiezorekSVPSell1,500$50.76$76,140.0017,311View SEC Filing  
11/25/2016Cynthia M ButittaCOOSell10,000$50.40$504,000.00105,477View SEC Filing  
10/3/2016Jeffrey WiezorekSVPSell1,500$54.81$82,215.0017,311View SEC Filing  
9/26/2016Cynthia M ButittaCOOSell10,000$54.13$541,300.00105,477View SEC Filing  
9/1/2016Jeffrey WiezorekSVPSell1,500$58.24$87,360.00View SEC Filing  
8/25/2016Cynthia M. ButittaCOOSell10,000$58.28$582,800.00View SEC Filing  
8/15/2016Helen Susan KimEVPSell35,900$60.27$2,163,693.0042,500View SEC Filing  
8/1/2016Jeffrey WiezorekSVPSell1,500$56.90$85,350.0016,367View SEC Filing  
7/25/2016Cynthia M ButittaCOOSell10,000$50.94$509,400.00105,401View SEC Filing  
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.0016,367View SEC Filing  
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00105,401View SEC Filing  
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00136,017View SEC Filing  
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.0016,367View SEC Filing  
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00105,401View SEC Filing  
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.0023,867View SEC Filing  
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.3818,155View SEC Filing  
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.0018,711View SEC Filing  
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00105,401View SEC Filing  
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.929,098View SEC Filing  
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.368,741View SEC Filing  
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.009,098View SEC Filing  
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.0094,007View SEC Filing  
2/1/2016Marc BetterVPSell9,000$47.34$426,060.007,688View SEC Filing  
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.0094,007View SEC Filing  
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.838,741View SEC Filing  
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.0013,742View SEC Filing  
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.909,098View SEC Filing  
1/4/2016Marc BetterVPSell9,000$61.53$553,770.007,688View SEC Filing  
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.0094,007View SEC Filing  
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.0075,507View SEC Filing  
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.006,342View SEC Filing  
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.202,198View SEC Filing  
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.712,941View SEC Filing  
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.006,904View SEC Filing  
11/2/2015Marc BetterVPSell9,000$71.07$639,630.001,888View SEC Filing  
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.0075,507View SEC Filing  
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.006,342View SEC Filing  
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.652,198View SEC Filing  
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.862,941View SEC Filing  
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.006,904View SEC Filing  
10/1/2015Marc BetterVPSell9,000$54.81$493,290.001,888View SEC Filing  
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.0075,507View SEC Filing  
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.852,198View SEC Filing  
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.122,941View SEC Filing  
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.006,904View SEC Filing  
9/1/2015Marc BetterVPSell9,000$51.81$466,290.001,888View SEC Filing  
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.0075,507View SEC Filing  
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kite Pharma (NASDAQ KITE) News Headlines

Source:
DateHeadline
Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European ExpansionsYour Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions
seekingalpha.com - May 17 at 8:20 AM
Global Gene Therapy Market Competitive landscape: Amgen Inc, Novartis, Transgene SA, Kite Pharma IncGlobal Gene Therapy Market Competitive landscape: Amgen Inc, Novartis, Transgene SA, Kite Pharma Inc
www.marketwatch.com - May 8 at 8:16 AM
A cancer treatment that one expert called the most exciting thing Ive seen in my lifetime just got approved to treat more ...A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to treat more ...
www.businessinsider.com - May 1 at 5:18 PM
Gilead hepatitis C drug sales slump, shares fall 5 pctGilead hepatitis C drug sales slump, shares fall 5 pct
www.nasdaq.com - May 1 at 5:18 PM
Apple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUSApple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUS
www.zacks.com - May 1 at 5:18 PM
Big Pharmas Strategy Is Music to Biotech Investors EarsBig Pharma's Strategy Is Music to Biotech Investors' Ears
www.wsj.com - May 1 at 5:18 PM
Gilead Tumbles After Revenue, Earnings Per Share Fall ShortGilead Tumbles After Revenue, Earnings Per Share Fall Short
www.bloomberg.com - May 1 at 5:18 PM
Kite Pharma (KITE) Given a $115.00 Price Target at Canaccord GenuityKite Pharma (KITE) Given a $115.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 20 at 3:01 PM
Astellas sells certain U.S. research facilities to GileadAstellas sells certain U.S. research facilities to Gilead
seekingalpha.com - April 19 at 8:15 AM
Patient advocate, aiming to deliver the right cancer treatments to the right patients, raises fresh round of cashPatient advocate, aiming to deliver the right cancer treatments to the right patients, raises fresh round of cash
www.bizjournals.com - April 18 at 8:16 AM
Gilead: Yescarta Faces Unforeseen HurdlesGilead: Yescarta Faces Unforeseen Hurdles
seekingalpha.com - April 16 at 8:15 AM
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms RaceGoldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race
fortune.com - April 13 at 5:33 PM
Kite Pharma (KITE) Downgraded to Hold at VetrKite Pharma (KITE) Downgraded to Hold at Vetr
www.americanbankingnews.com - April 13 at 10:15 AM
Canaccord Genuity Analysts Give Kite Pharma (KITE) a $120.00 Price TargetCanaccord Genuity Analysts Give Kite Pharma (KITE) a $120.00 Price Target
www.americanbankingnews.com - April 11 at 8:26 PM
Kite Pharma (KITE) Earns "Hold" Rating from Stifel NicolausKite Pharma (KITE) Earns "Hold" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 11 at 3:24 PM
Kite Pharma (KITE) Downgraded to "Hold" at Canaccord GenuityKite Pharma (KITE) Downgraded to "Hold" at Canaccord Genuity
www.americanbankingnews.com - April 9 at 8:06 PM
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology PortfolioPfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
finance.yahoo.com - April 3 at 5:36 PM
A CEO who sold his last cancer drug company for $12 billion just got $300 million to do it againA CEO who sold his last cancer drug company for $12 billion just got $300 million to do it again
www.msn.com - April 3 at 5:36 PM
Theyre Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment AgainThey're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again
www.forbes.com - April 3 at 8:21 AM
BioSci Specialty Report On The Novel Cancer Treatment CAR-TCRBioSci Specialty Report On The Novel Cancer Treatment CAR-TCR
seekingalpha.com - March 29 at 8:25 AM
Peloton Therapeutics, Inc. Appoints Helen S. Kim, MBA and David Chang, MD, Ph.D. to Board of Directors - Business Wire (press release)Peloton Therapeutics, Inc. Appoints Helen S. Kim, MBA and David Chang, MD, Ph.D. to Board of Directors - Business Wire (press release)
www.businesswire.com - March 22 at 8:23 AM
Head-To-Head Review: Kite Pharma (KITE) & Nexvet Biopharma (NVET)Head-To-Head Review: Kite Pharma (KITE) & Nexvet Biopharma (NVET)
www.americanbankingnews.com - March 20 at 7:10 PM
Gilead is making a $3.1 billion bet on an experimental editing technology for cancer treatmentsGilead is making a $3.1 billion bet on an experimental editing technology for cancer treatments
www.businessinsider.com - February 22 at 5:38 PM
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
www.msn.com - February 22 at 5:38 PM
Sangamo in $3 billion gene-editing deal with Gilead - ReutersSangamo in $3 billion gene-editing deal with Gilead - Reuters
www.reuters.com - February 22 at 8:20 AM
Paul Hastings lands at startup aimed at cancers natural killer - San Francisco Business TimesPaul Hastings lands at startup aimed at cancer's 'natural killer' - San Francisco Business Times
www.bizjournals.com - February 20 at 8:16 AM
Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian? - Seeking AlphaMerger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian? - Seeking Alpha
seekingalpha.com - February 18 at 8:16 AM
CORRECTED-Gilead Q4 hepatitis C drug sales plummet, shrs drop 3 pct after hoursCORRECTED-Gilead Q4 hepatitis C drug sales plummet, shrs drop 3 pct after hours
www.reuters.com - February 7 at 9:34 AM
Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholders - GlobeNewswire (press release)Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholders - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:40 PM
Bluebird Bio Up On Buyout Speculation After Celgene-Juno DealBluebird Bio Up On Buyout Speculation After Celgene-Juno Deal
www.benzinga.com - January 25 at 9:27 AM
With $9 Billion Juno Deal, Celgene Doubles Down on CancerWith $9 Billion Juno Deal, Celgene Doubles Down on Cancer
www.bloomberg.com - January 22 at 3:52 PM
Big Drugmakers Pay Big Prices for Promising BiotechsBig Drugmakers Pay Big Prices for Promising Biotechs
www.wsj.com - January 22 at 3:52 PM
The case for Gilead Sciences - Motley FoolThe case for Gilead Sciences - Motley Fool
www.fool.com - January 22 at 8:08 AM
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion - BloombergSanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion - Bloomberg
www.bloomberg.com - January 22 at 8:08 AM
Juno Hits 52-Week High on Celgenes Rumored Buyout InterestJuno Hits 52-Week High on Celgene's Rumored Buyout Interest
www.zacks.com - January 18 at 3:34 PM
Juno Therapeutics (JUNO) Surges on Takeover Report as Wall Street Debates Potential Deal ValuationJuno Therapeutics (JUNO) Surges on Takeover Report as Wall Street Debates Potential Deal Valuation
www.streetinsider.com - January 17 at 3:32 PM
2018 Is Gileads Year - Gilead Sciences, Inc. (NASDAQ:GILD ... - Seeking Alpha2018 Is Gilead's Year - Gilead Sciences, Inc. (NASDAQ:GILD ... - Seeking Alpha
seekingalpha.com - January 16 at 3:31 PM
2018 Is Gileads Year - Gilead Sciences, Inc. (NASDAQ:GILD ... - Seeking Alpha2018 Is Gilead's Year - Gilead Sciences, Inc. (NASDAQ:GILD ... - Seeking Alpha
seekingalpha.com - January 16 at 3:31 PM
Can Biotech Keep Last Years Momentum Alive in 2018? - NasdaqCan Biotech Keep Last Year's Momentum Alive in 2018? - Nasdaq
www.nasdaq.com - January 11 at 3:33 PM
Can Biotech Keep Last Years Momentum Alive in 2018?Can Biotech Keep Last Year's Momentum Alive in 2018?
www.zacks.com - January 11 at 10:58 AM
Bolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit - BloombergBolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit - Bloomberg
www.bloomberg.com - January 9 at 3:32 PM
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer - GlobeNewswire (press release)UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer - GlobeNewswire (press release)
globenewswire.com - January 9 at 3:32 PM
Why 2017 Was a Year to Remember for Gilead Sciences, Inc. - Motley FoolWhy 2017 Was a Year to Remember for Gilead Sciences, Inc. - Motley Fool
www.fool.com - January 5 at 3:33 PM
2018 Biotech preview: The biotech industry aims to find solutions for the worst maladies - San Francisco Business Times2018 Biotech preview: The biotech industry aims to find solutions for the worst maladies - San Francisco Business Times
www.bizjournals.com - January 4 at 3:32 PM
Gilead Might Want To Consider Selling Its HCV Drug Business To China - Seeking AlphaGilead Might Want To Consider Selling Its HCV Drug Business To China - Seeking Alpha
seekingalpha.com - January 2 at 8:45 PM
The Intrinsic Value Of Gilead ScienceThe Intrinsic Value Of Gilead Science
www.forbes.com - January 1 at 3:32 PM
What The Cell Design Labs Acquisition Means For Gilead? - Seeking AlphaWhat The Cell Design Labs Acquisition Means For Gilead? - Seeking Alpha
seekingalpha.com - December 18 at 3:31 PM
Financial Contrast: Kite Pharma (KITE) and Its PeersFinancial Contrast: Kite Pharma (KITE) and Its Peers
www.americanbankingnews.com - December 16 at 5:16 AM
CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & MoreCAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
www.zacks.com - December 15 at 3:35 PM
Dont Count on Gilead Buying GalapagosDon't Count on Gilead Buying Galapagos
finance.yahoo.com - December 15 at 3:35 PM

SEC Filings

Kite Pharma (NASDAQ:KITE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kite Pharma (NASDAQ:KITE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kite Pharma (NASDAQ KITE) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.